COVID-19 did not have a long-term effect on the disease course of inflammatory bowel disease (IBD), according to a study published online in November. 4 inches Therapeutic Advances in Gastroenterology.
Simon J. Hong, MD, of NYU Langone Health in New York City, and colleagues assessed the impact of COVID-19 on the long-term outcome of IBD. The analysis included 251 cases (45 percent ulcerative colitis; 55 percent Crohn’s disease) and 251 controls, with a median follow-up of 394 days.
The researchers found that the primary composite outcome of IBD-related hospitalization or surgery occurred in 29 cases (12 percent) versus 38 controls (15 percent). COVID-19 was not associated with an increased risk of adverse IBD outcomes (adjusted hazard ratio, 0.84; 95 percent confidence interval, 0.44 to 1.42). There was also no significant difference in adverse IBD outcomes based on the severity of COVID-19 (adjusted hazard ratios [95 percent confidence intervals]2.43 [1.00 to 5.86] oath 0.68 [0.38 to 1.23] due to severe COVID-19 and mild to moderate COVID-19, respectively).
“In this multicenter study, COVID-19 did not alter the long-term course of IBD; however, severe COVID-19 may portend a worse IBD disease course and prognosis,” the authors write. “Risk reduction and vaccination remain important strategies in the care of IBD patients during the COVID-19 pandemic.”
Several authors reported financial relationships with the pharmaceutical industry.
Copyright © 2022 HealthDay. All rights reserved.
Quotation: COVID-19 not linked to worse inflammatory bowel disease outcomes (2022, November 18) retrieved November 20, 2022 from https://medicalxpress.com/news/2022-11-covid-worse-inflammatory-bowel-disease.html
This document is subject to copyright. Except for fair dealing for the purpose of private research or study, no part may be reproduced without written permission. The material is provided for informational purposes only.